197 related articles for article (PubMed ID: 35853853)
1. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
[TBL] [Abstract][Full Text] [Related]
2. The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.
Klein DC; Lardo SM; Hainer SJ
Cancer Res Commun; 2024 Jan; 4(1):237-252. PubMed ID: 38126767
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
[TBL] [Abstract][Full Text] [Related]
4. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition.
Del Gaudio N; Di Costanzo A; Liu NQ; Conte L; Migliaccio A; Vermeulen M; Martens JHA; Stunnenberg HG; Nebbioso A; Altucci L
Cell Death Dis; 2019 Apr; 10(5):338. PubMed ID: 31000698
[TBL] [Abstract][Full Text] [Related]
5. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K; Samur MK; Liow P; Wen K; Yamamoto L; Liu J; Morelli E; Gulla A; Tai YT; Qi J; Hideshima T; Anderson KC
Clin Cancer Res; 2023 May; 29(9):1807-1821. PubMed ID: 36780189
[TBL] [Abstract][Full Text] [Related]
6. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
Remillard D; Buckley DL; Paulk J; Brien GL; Sonnett M; Seo HS; Dastjerdi S; Wühr M; Dhe-Paganon S; Armstrong SA; Bradner JE
Angew Chem Int Ed Engl; 2017 May; 56(21):5738-5743. PubMed ID: 28418626
[TBL] [Abstract][Full Text] [Related]
7. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4.
Ahmed NS; Gatchalian J; Ho J; Burns MJ; Hah N; Wei Z; Downes M; Evans RM; Hargreaves DC
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34983841
[TBL] [Abstract][Full Text] [Related]
8. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Chowdhury B; Garg S; Ni W; Sattler M; Sanchez D; Meng C; Akatsu T; Stone R; Forrester W; Harrington E; Buhrlage SJ; Griffin JD; Weisberg E
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610997
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
10. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
11. BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state.
Xiao M; Kondo S; Nomura M; Kato S; Nishimura K; Zang W; Zhang Y; Akashi T; Viny A; Shigehiro T; Ikawa T; Yamazaki H; Fukumoto M; Tanaka A; Hayashi Y; Koike Y; Aoyama Y; Ito H; Nishikawa H; Kitamura T; Kanai A; Yokoyama A; Fujiwara T; Goyama S; Noguchi H; Lee SC; Toyoda A; Hinohara K; Abdel-Wahab O; Inoue D
Nat Commun; 2023 Dec; 14(1):8372. PubMed ID: 38102116
[TBL] [Abstract][Full Text] [Related]
12. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity.
Wang L; Oh TG; Magida J; Estepa G; Obayomi SMB; Chong LW; Gatchalian J; Yu RT; Atkins AR; Hargreaves D; Downes M; Wei Z; Evans RM
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34446564
[TBL] [Abstract][Full Text] [Related]
14. BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells.
Wang X; Song C; Ye Y; Gu Y; Li X; Chen P; Leng D; Xiao J; Wu H; Xie S; Liu W; Zhao Q; Chen D; Chen X; Wu Q; Chen G; Zhang W
Nucleic Acids Res; 2023 Nov; 51(21):11634-11651. PubMed ID: 37870468
[TBL] [Abstract][Full Text] [Related]
15. Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells.
Zhou L; Yao Q; Li H; Chen J
Transl Cancer Res; 2021 Jul; 10(7):3364-3372. PubMed ID: 35116642
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
17. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
20. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
